Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Provided By GlobeNewswire
Last update: Aug 6, 2025
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications
Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025
Read more at globenewswire.com
